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Abstract 
High levels of acute phase reactants can be associated with adverse outcome in patients with 
various solid tumor types. For patients with acute myeloid leukemia (AML), this correlation is 
unknown. We retrospectively investigated the prognostic value of pretreatment acute phase 
protein levels in 282 consecutive newly diagnosed AML patients undergoing at least one cycle 
of intensive induction chemotherapy. We applied a new score integrating pre-treatment C-
reactive protein (CRP), fibrinogen, and albumin levels termed the CFA ratio, and we stratified 
patients into two groups: Patients with a CFA ratio below 3.06 had decisively better 
progression free (26.2 vs. 7.7 months; P<.001), disease free (56.4 vs. 8.7 months; P<.001) 
and overall survival (61.2 vs. 13.8 months; P<.001). Results remained significant when 
adjusting for confounders including ELN risk group. Early mortality also tended to be lower in 
the low CFA ratio group. Finally, patients with lower modified Glasgow prognostic score 
(mGPS) similarly had better outcome. In conclusion, our data suggest that an elevated CFA 
ratio as well as a high mGPS are associated with adverse outcome in patients with newly 
diagnosed AML undergoing intensive induction. These parameters should undergo 
prospective evaluation for their contribution to risk profiling in AML patients.  
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Introduction 
The complex interplay between inflammation and cancer development was suggested already 
in the 19th century1, and it may best be exemplified by the increased risk for colorectal cancer 
in patients with chronic bowel disease including Crohn’s disease or ulcerative colitis.2 
Therefore, the role of acute phase proteins has not only been investigated during inflammatory 
disorders, but similarly in malignancies. Among acute phase reactants, C-reactive protein 
(CRP) and fibrinogen are produced by hepatocytes upon tissue damage or infection through 
interleukin (particularly IL-6 and IL-1) and TNF-alpha signaling pathways.3,4 During 
inflammatory processes, such mediators are elevated, whereas levels of “negative” acute 
phase reactants such as serum albumin and transferrin decrease due to lowered synthesis or 
increased degradation.5 Upon secretion, CRP circulates in the plasma where it recognizes 
and eliminates pathogens by binding to cells and subsequently activating the complement 
system6. Fibrinogen exerts a key role within the coagulation cascade by mediating platelet 
aggregation and providing the substrate for clot formation upon conversion to fibrin by 
thrombin.7 Serum albumin is the most abundant blood protein and essential for maintaining 
oncotic homeostasis, as well as serving as a carrier protein for small hydrophobic molecules 
including steroids, hormones, therapeutic compounds, and toxins.8,9 Tumor growth can lead 
to inflammation, which, in turn, can trigger the synthesis of acute phase proteins.10 CRP is 
elevated in chronic inflammatory conditions, it can promote tumor growth and may reflect 
various types of immune responses following presentation of tumor antigens.11 Inflammatory 
proteins can also be produced by cancer cells themselves as there is evidence of expression 
of CRP, IL-6 and IL-8 in various cancer cell types and cell lines.12–14 
The CRP/albumin ratio has been investigated in various solid tumors including hepatocellular 
carcinoma,15 non-small cell lung cancer,16 ovarian17 and pancreatic adenocarcinomas.18 In 
these studies, high levels of acute phase proteins as expressed by an elevated ratio (high 
CRP and/or low albumin) were consistently associated with adverse outcome.  By allocating 
points for different levels of CRP and albumin, the Glasgow prognostic score (GPS) and 
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modified GPS (mGPS) can be used to describe the acute phase protein status of a given 
patient. It has been shown to have prognostic significance in a variety of solid tumors19 as well 
as hematologic malignancies including peripheral T-cell lymphoma,20 DLBCL21 or advanced 
Hodgkin’s lymphoma. Moreover, the score has been shown to predict treatment tolerance in 
patients with head and neck cancer.22 .  
In acute myeloid leukemia (AML) and other hematologic malignancies, pro- and anti-
inflammatory cytokines were suggested to be relevant for the pathogenesis and progression 
of these diseases. Population-based studies indicated that patients with a history of infectious 
or autoimmune disease had an increased risk of developing AML.23,24 Dysregulation of 
cytokine expression, as a hallmark of chronic inflammation and autoimmunity, is promoting 
the development of hematologic malignancies.25 Elevated pretreatment CRP levels were 
associated with adverse outcome in patients with DLBCL in a meta-analysis.26 We recently 
reported that elevated fibrinogen levels were associated with adverse survival in newly 
diagnosed AML patients.27 Moreover, increased serum ferritin levels were predictive of 
adverse overall and relapse-free survival in young intermediate-risk AML patients28 and, also, 
in a cohort of AML patients when adjusting for CRP levels.29 Elevated pretreatment CRP and 
ferritin levels were positively associated with the incidence of systemic inflammation during 
anti-leukemic induction chemotherapy.30 Albumin was reported to be an independent 
prognostic factor and a superior parameter compared to the body mass index to evaluate the 
nutritional status in newly diagnosed AML patients.31 To the best of our knowledge, however, 
no study has investigated so far how CRP or albumin levels at diagnosis may affect survival 
in AML patients, and the Glasgow prognostic score has not been verified for AML patients. In 
this study, we aimed to investigate whether levels of acute phase reactants at diagnosis 
correlate with survival or response to intensive induction chemotherapy in newly diagnosed 
AML patients. Ultimately, we evaluated the CFA ratio, a novel simple score based on acute 
phase protein levels, whether it can provide relevant prognostic information in AML patients 
at diagnosis.  
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Methods 
Patients: This retrospective single-center analysis included data of consecutive patients with 
a first diagnosis of AML between 2000 and 2018 at the University Hospital of Bern, 
Switzerland. De novo and secondary AML were included. We limited our analysis to AML 
patients between 18 and 65 years at the time of diagnosis and they had to undergo at least 
one cycle of intensive chemotherapy with curative intent. Data were collected for gender, age, 
hemoglobin, white blood cell and neutrophil counts, platelets, bone marrow infiltration and 
peripheral blasts, C-reactive protein, albumin, fibrinogen, as well as for molecular and 
cytogenetic abnormalities and for blood and bone marrow assessments following treatment 
and during follow-up.  
Treatment: Patients were treated within or according to the following protocols of the HOVON 
(Dutch-Belgian hemato-oncology group) and SAKK (Swiss group for clinical cancer research) 
AML groups: SAKK/ HOVON-42, -81, -92, -102, and -132; or of the APL (French-Belgian-
Swiss APL) group: APL-2000 and APL-2006. Induction treatment for AML patients consisted 
of one or two cycles of cytarabine and an anthracycline (either idarubicin or daunorubicin). 
Consolidation therapy consisted of either additional cycles of chemotherapy or high-dose 
chemotherapy followed by autologous or allogeneic hematopoietic stem cell transplantation in 
favorable or intermediate-risk patients, or in allogeneic transplantation for adverse-risk 
patients. Patients had to have an Eastern cooperative oncology group performance status of 
0-2 and were not previously treated for AML with the exception of hydroxyurea for initial 
cytoreduction.  
Definitions: Response was assessed according to international working group criteria.32 
Morphologic complete remission (CR) was defined as bone marrow blasts of <5% with 
complete hematologic recovery (neutrophils (ANC) ≥1.0G/L, platelets ≥100 G/L, and no 
transfusion dependence). Complete remission with incomplete hematologic recovery (iCR) 
was defined as bone marrow blasts of <5% with neutrophils <1.0 G/L and/or platelets <100 
G/L. Progression free survival was defined as the time from diagnosis to progression or death 
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from any cause or last follow-up whichever occurred first. Overall survival was the time 
between diagnosis and death from any cause or until last follow-up. Disease free survival was 
the time between CR and relapse or death from any cause or last follow-up. Subjects lost to 
follow-up were censored at the time last known to be alive. Genetic risk profiling was applied 
according to the European Leukemia Network (ELN) update from 2017.33  
Development of a novel acute phase protein score: Reference levels for the serum acute 
phase proteins were as follows: CRP: <5 mg/L; fibrinogen: 1.8 - 4.0 g/L; and albumin: 35 - 52 
g/L. The CRP*fibrinogen/albumin (CFA) ratio was calculated as follows:  
CRP (mg L⁄ ) ∗ Fibrinogen (g L)⁄
Albumin (g L⁄ )
 
When considered as a numeric value, this index showed positive skew. Therefore, natural 
logarithms were applied in subsequent analyses, which allowed for a more symmetric 
distribution. The cutoff was determined using the minimum P value approach with multiple log-
rank tests. To correct for increasing type I errors, the method proposed by Miller and Siegmund 
was used.34  
Calculation of GPS and mGPS: To calculate the GPS, one point was given for CRP >10 
mg/L and/or albumin <35 g/L. For mGPS, one point for hypoalbuminemia was only awarded 
in the presence of elevated CRP levels (>10 mg/L), as previously described.19  
Statistical analyses: Survival curves and analyses were calculated using the Kaplan-Meier 
and log-rank method, respectively. Hazard ratios to evaluate the impact of baseline 
characteristics to clinical outcome were calculated using the log-rank method. To adjust for 
factors associated with outcome, we performed a multivariate stratified cox model with the co-
variables Log(CRP*fibrinogen/albumin), Log(Lc) and bone marrow blasts (all as numeric 
values) for each ELN risk group (favorable, intermediate and adverse).33 Reported P values 
for baseline characteristics were from two-tailed Mann-Whitney or unpaired t-tests, and a 
value of P<.05 was considered significant. Analyses were conducted in GraphPad Prism 
version 7.0 (Graphpad Software, Inc., La Jolla, CA, USA) and R version 3.4.4 (R Foundation, 
Vienna, Austria).   
 
©2019 American Geophysical Union. All rights reserved. 
Results 
Patients: We identified 282 consecutive patients with newly diagnosed AML aged ≤65 years 
receiving at least one cycle of induction chemotherapy with complete data sets available for 
CRP, fibrinogen and albumin serum levels. All patients were at first diagnosis of AML before 
initiation of intensive induction treatment. We summarized the clinical characteristics of all 
patients in Table 1. Distribution of acute phase protein levels is shown in Supplemental 
Figure 1.  
Comparison of disease characteristics in patients with high versus low CFA ratio: 
According to the method by Miller and Siegmund,34 the optimal cutoff for the CFA ratio for 
stratification was determined at 3.06 for the survival rates, and patients were dichotomized 
into two cohorts accordingly (high CFA versus low CFA ratio). Hemoglobin and platelet level, 
age, gender, and FAB classification did not differ between both groups. ELN risk groups and 
individual cyto- and molecular genetic characteristics were similar with the exception of FLT3-
ITD/NPM1 wild-type, which was more common within the higher CFA ratio group (10.7 vs. 
1.2%, P<.001). The proportions of patients undergoing autologous or allogeneic stem cell 
transplantations were similar in the low and high CFA ratio cohorts (autologous SCT 38.2 vs. 
33.6%, P=.455; allogeneic SCT 28.8 vs. 22.1%, P=.220). Differences were observed for 
peripheral leukocytes and blast counts at diagnosis, which both were higher in the high CFA 
ratio cohort (median leukocytes 46.9 vs. 25.2G/L, P=.009; median peripheral blasts 51.0 vs. 
38.7%, P=.001; and median marrow blasts 71.4 vs. 62.3%, P=.003). We observed no 
differences in DIC rates in APL patients as defined by an ISTH DIC score of ≥5 between the 
high and low CFA ratio groups (83.3 vs. 78.6%, P>.999). 
Clinical relevance of the novel CFA ratio: Survival data comparing high CFA versus low 
CFA ratio groups were summarized in Figure 1 and Table 2. We observed that the median 
progression free survival in the low CFA ratio group was higher than in the high CFA ratio 
group (26.2 vs. 7.7 months; P<.001). Similarly, median disease-free (56.4 vs. 8.7 months; 
P<.001) and overall survival (61.2 vs. 13.8 months; P<.001) were longer in the low CFA ratio 
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group. Response to induction treatment was better in the low ratio group with CR rates of 89% 
vs. 76%, respectively (P=.006). When adjusting for potential confounders in a multivariate 
analysis including CFA ratio, peripheral leukocytes, and bone marrow blasts, results for 
progression free and overall survival remained significant (Adjusted HR 1.14 (1.05-1.25, 
P=.003); and 1.19 (1.08-1.31, P<.001; Table 3). Early mortality tended to be higher in the high 
CFA ratio group (9 vs. 6% after 1 month, P=.350; 20 vs. 11% after 3 months; P=.063), with 
this difference being significant 6 months after initiation of therapy (34 vs. 20%, P=.013). 
Clinical impact of the (modified) Glasgow prognostic score and mGPS: Next, we 
investigated the prognostic relevance of the GPS and mGPS in AML patients. Results were 
summarized in Supplemental Table 1. Stratification of patients according to GPS indicated 
the best median PFS of 26.2 months for patients with GPS score 0, of 12.6 months for GPS 
score 1, and 9.0 months for GPS score 2 (P=.154). Similarly, the median DFS was 56.4 
months (score 0), 16.8 months (score 1), and 13.2 months (score 2; P=.477). The median OS 
were 61.2 months, 24.0 months and 15.7 months, respectively (P=.082).  
When patients were stratified according to mGPS, we observed a median PFS of 26.8 months 
(mGPS 0), 11.9 months (mGPS 1), and 9.0 months (mGPS 2, P=.051). The median DFS were 
30.8 months, 14.2 months, and 13.2 months (P=.2512), and the median OS were 61.2 months, 
21.2 months, and 15.7 months (P=.026). The difference was evident between mGPS score 0 
and 1 patients, whereas survival curves between mGPS 1 and 2 appeared similar. Finally, 
when comparing patients with mGPS 0 to patients with combined mGPS 1 and 2, survival 
differences were significant (Supplemental Figure 2). 
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Discussion 
In this retrospective, single-center analysis we aimed to investigate the prognostic significance 
of pretreatment acute phase protein levels on outcome in newly diagnosed AML patients 
undergoing intensive induction chemotherapy. We recently reported that elevated levels of 
fibrinogen are associated with adverse outcome in newly diagnosed AML patients.27 Elevated 
levels of acute phase proteins as well as CRP/albumin ratio were linked to adverse outcome 
in various solid tumors as well as hematologic malignancies. To the best of our knowledge, 
this association so far has not been investigated in AML patients.  
An elevated GPS has been shown to be associated with weight loss,35–38 poor performance 
status35 and reduced dietary intake38 in patients with solid tumors. Moreover, the GPS has 
been shown to predict increased toxicity in patients undergoing chemotherapy.39,40 In this 
study, we developed a novel score termed CFA ratio, which includes pretreatment CRP, 
fibrinogen, and albumin levels. When applying this novel score to a large cohort of AML 
patients undergoing intensive induction treatment, we observed that patients with higher CFA 
ratios had shorter progression-free, disease-free and overall survival as compared to patients 
with lower CFA ratios. In particular, a CFA ratio >3.06 was associated with adverse survival. 
Analyses for PFS and OS remained significant when adjusting for potential confounders in a 
multivariate analysis. Finally, patients with a higher CFA ratio also had lower CR rates. While 
early mortality tended to be higher in the high CFA ratio group, this was only significant after 
6 months. A recent analysis showed a decrease in early mortality during induction therapy in 
AML patients from 2006 to 2016.41 As our analysis includes patients treated between 2000 
and 2018, comparison of early mortality may be biased by time period.   
In a previous analysis, we found that AML patients with high versus low fibrinogen levels did 
not differ in the incidence of thromboembolic events or the frequency of bleeding.23 Therefore, 
the integration of fibrinogen into the CFA ratio highlighted its relevance as an acute phase 
protein and to be independent in this large cohort from bleeding and coagulopathy as 
demonstrated by similar DIC rates between the two groups. In addition, we could demonstrate 
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that the original and the modified Glasgow prognostic score (GPS and mGPS), which have 
been verified in many solid tumor types, also has prognostic significance in AML patients. We 
found that AML patients with lower scores of the GPS and the mGPS had better survival rates. 
In particular, an mGPS score of 0 was associated with superior progression free, disease free 
and overall survival compared to scores ≥1. We did not directly compare the Glasgow 
prognostic score to our novel CFA ratio, however, the inclusion of Fibrinogen to the 
CRP/Albumin ratio led to enhanced statistical significance. Therefore, the CFA ratio can be 
considered as an easily applicable clinical score. 
Inflammatory processes have been reported to play an important role in the proliferation of 
myeloid blasts.42,43 Since cytokines influence signal transduction in hematopoietic cells, 
abnormal cytokine release through activity of inflammatory cells or leukemic precursor cells 
was reported to suppress apoptosis and differentiation of precursor cells leading to increased 
proliferation.44 Anti-inflammatory cytokines such as TGF-ß inhibit proliferation of leukemic cells 
and control the expression of pro-inflammatory cytokines such as IL-1 or IL-6. Thus, 
downregulation of anti-inflammatory cytokines may lead to a predominance of pro-
inflammatory and therefore pro-leukemic cytokines.25 It can be postulated that an elevated 
CFA ratio or mGPS represents the underlying cytokine dysregulation. While it has been shown 
that levels of all IL-1, IL-6 and CRP are higher in cancer patients than in healthy controls, 
correlation of cytokines and acute phase protein levels is weak at best.45,46 Therefore, it 
remains unclear whether adverse prognosis in AML patients with high CFA ratio is due to poor 
performance status and impaired tolerance of therapy or whether a higher ratio can be 
considered as hallmark of a more aggressive disease by a yet unknown mechanism.  
Assessment of prognosis of AML patients mostly relies on pretreatment molecular and 
cytogenetic methods. While a number of driver mutations with known prognostic significance 
has been previously identified, novel mutations with yet unknown relation to disease 
progression or prognosis are currently discovered by next-generation sequencing (NGS) 
technique.47 Novel approaches focus on post-treatment assessment of leukemic stem cell 
frequency by flow cytometry in combination with traditional flow minimal residual disease 
 
©2019 American Geophysical Union. All rights reserved. 
(MRD) strategies, but this approach is so far only available in few laboratories.48 Parameters 
such as fibrinogen, CRP and albumin on the other hand are routinely assessed and laboratory 
tests yield results within minutes. Therefore, scores based on acute phase proteins, such as 
the CFA ratio proposed in this work or the (m)GPS may provide an additional, rapidly available 
initial assessment of prognosis and risk upon diagnosis and may thereby contribute to patient 
information. During induction and consolidation treatment, the CFA score can offer a more 
differentiated mean of risk profiling and may lead to adaptation of surveillance strategies.  
As our analysis is limited by its single-center, retrospective character, the CFA ratio may be 
independently validated by prospective multicenter approaches with validation cohorts. Due 
to missing data, a reliable statement about the performance status of patients in our analysis 
is not possible, however, all included patients were deemed fit for intensive treatment. Thus, 
collaborative leukemia study groups may investigate whether an increased CFA ratio and 
imbalances in acute phase reactants reflect an adverse performance status or whether they 
are a yet unknown surrogate marker for a more aggressive course of AML. As AML is a 
disease of the elderly and patients often present in a bad performance status unfit for intensive 
treatment, the CFA score could also be validated in a non-intensively treated cohort.  
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Table 1: Patient and disease characteristics 
Parameter 
Low CFA ratio  
(n=160) 
High CFA ratio 
(n=122) 
P s 
Hemoglobin (g/L) 94.2 (±22.2) 91.8 (±22.5) .373 ns 
Leukocytes (G/L)  25.2 (±39.8) 46.9 (±74.2) .009 ** 
Neutrophils (G/L)  3.2 (±7.7) 3.0 (±4.7) .976 ns 
Peripheral blasts (%)  38.7 (±31.3) 51.0 (±30.5) .001 ** 
Bone marrow blasts (%)  62.3 (±26.1) 71.4 (±25.5) .003 ** 
Platelets (G/L)  91.0 (±89.6) 82.4 (±84.0) .337 ns 
Gender, female/male  80/80 (50%/50%) 50/72 (41%/59%) .149 ns 
Age, years (range) 50.3 (19.3-65.9) 51.4 (19.9-65.8) .441 ns 
FAB Classification     
M0 20 (12%) 11 (9%) .443 ns 
M1 28 (18%) 22 (18%) >.999 ns 
M2 37 (23%) 28 (23%) >.999 ns 
M3 17 (11%) 8 (7%) .292 ns 
M4 26 (16%) 29 (24%) .130 ns 
M5 10 (6%) 9 (7%) .812 ns 
M6 5 (3%) 1 (1%) .239 ns 
M7 1 (1%) 4 (3%) >.999 ns 
unclassifiable 16 (10%) 10 (8%) .681 ns 
ELN risk stratification     
Favorable 61 (38%) 33 (27%) .056 ns 
mNPM1 w/o FLT3-ITD 19 (12%) 12 (9%) .702 ns 
t(15;17)/PML-RARA 17 (11%) 8 (7%) .233 ns 
t(8;21)/RUNX1-RUNX1T1 12 (8%) 8 (7%) .819 ns 
inv(16)/CBFB-MYH11 7 (4%) 3 (2%) .522 ns 
CEBPA 6 (3%) 2 (2%) .473 ns 
Intermediate 66 (41%) 54 (44%) .629 ns 
NOS 49 (31%) 39 (33%) .897 ns 
mNPM1 w/ FLT3-ITD 8 (5%) 10 (8%) .329 ns 
wtNPM1 w/o FLT3-ITD 7 (4%) 4 (3%) .762 ns 
t(9;11)/MLLT3-KMT2A 2 (1%) 1 (1%) >.999 ns 
Adverse 33 (21%) 35 (29%) .878 ns 
Monosomy or complex 26 (16%) 16 (13%) .503 ns 
wtNPM1 w/ FLT3-ITD 2 (1%) 13 (11%) <.001 *** 
inv(3)/EVI1 rearranged 4 (3%) 3 (2%) >.999 ns 
t(v;11)/KMT2A rearranged 1 (1%) 2 (2%) .580 ns 
t(6;9)/DEK-NUP214 0 (0%) 1 (1%) .433 ns 
 
Laboratory analyses and age indicated as median values. Plus/minus values indicate standard deviation of the mean.  
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Table 2: Outcome  
 Low CFA ratio 
(n=160) 
High CFA ratio 
(n=122) 
P s 
Survival    
Progression free survival, months 26.2 7.7 <.001 *** 
Disease free survival, months 56.4 8.7 <.001 *** 
Overall survival, months 61.2 13.8 <.001 *** 
Follow up, months 56.2 54.7 - - 
Time to relapse, months 7.3 5.0 .135 ns 
Response to therapy     
CR achieved, n (%) 142 (89%) 93 (76%) .006 ** 
Relapse, n (%) 57 (36%) 49 (40%) .458 ns 
Mortality within 1 month, n (%) 9 (6%) 11 (9%) .350 ns 
Mortality within 3 months, n (%) 18 (11%) 24 (20%) .063 ns 
Mortality within 6 months, n (%) 32 (20%) 41 (34%) .013 * 
Mortality total, n (%) 74 (46%) 83 (68%) <.001 *** 
Death in CR1, n (%) 9 (6%) 12 (13%) .103 ns 
Stem cell transplant     
Autologous, n (%) 61 (38%) 41 (34%) .455 ns 
Allogeneic, n (%) 46 (29%) 27 (22%) .220 ns 
 
Survival rates indicated as median values; CR: complete remission; Death in CR1 indicated as percentage of patients 
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Table 3: Multivariate outcome analysis. 







PFS 0.621 1.8 (1.3-2.5) .003 1.14 (1.05-1.25) .003 
Log(CRP*Fib/Alb)  1.14 (1.05-1.25) .003 - - 
Log(Lc)  1.18 (1.07-1.31) .001 - - 
Bone marrow blasts  0.99 (0.99-1.00) .006 - - 
DFS 0.633 1.8 (1.3-2.5) .028 1.10 (0.99-1.22) .067 
Log(CRP*Fib/Alb)  1.10 (0.99-1.22) .067 - - 
Log(Lc)  1.23 (1.09-1.38) .001 - - 
Bone marrow blasts  0.99 (0.99-1.00) .026 - - 
OS 0.623 1.9 (1.4-2.7) .001 1.19 (1.08-1.31) <.001 
Log(CRP*Fib/Alb)  1.19 (1.08-1.31) <.001 - - 
Log(Lc)  1.13 (1.02-1.26) .018 - - 
Bone marrow blasts  0.99 (0.99-1.00) .002 - - 
 
Stratified Cox model, with covariables Log(CRP*Fib/Alb), Log(Lc) and bone marrow blasts (as continuous  variables) 
for each ELN risk class (favorable, intermediate, adverse). HR: hazard ratio; PFS: progression free survival; DFS: 
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Figure 1: Survival according to the CFA (CRP*Fibrinogen/Albumin)  ratio. Kaplan-Meier curves 
for progression free (A), disease free (B) and overall survival (C) according to CFA ratio.  
 
